Akebia Therapeutics price to sales ratio AKBA
Market value divided by revenue over the last twelve months, since 2019.
- Today, Nov 2, 2026
- 0.9×
- 7-year median
- 1.8×
- Against its 7-year history
- 21st
- percentile: 0 is its lowest day, 100 its highest
- 7-year range
- 0.2× to 5.6×
- Peer median
- 1.4×
Akebia Therapeutics' price to sales ratio is 0.9× as of Nov 2, 2026.
That is below its 7-year median of 1.8×, lower than on 79% of days in the last 7 years.
Over that time it ranged from 0.2× in Nov 2022 to 5.6× in Jun 2025.
The median for 10 large drugmakers of a similar size is 1.4×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.9× | 0.7× | 1.8× |
| 2025 | 2.0× | 1.8× | 5.6× |
| 2024 | n/m a value too high to mean anything | ||
| 2023 | 0.7× | 0.3× | 0.7× |
| 2022 | 0.4× | 0.2× | 2.2× |
| 2021 | 1.9× | 1.4× | 2.6× |
| 2020 | 1.3× | 0.9× | 4.9× |
| 2019 | 2.4× | 1.2× | 3.0× |
Against its peers
Companies in Drug Manufacturers - General nearest Akebia Therapeutics' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| AKBAAkebia Therapeutics | 0.9× |
| NATRNatures Sunshine Products | 0.4× |
| CRMDCorMedix | 0.9× |
| ARVNArvinas | 1.6× |
| LFVNLifevantage | 0.4× |
| PBYIPuma Biotechnology | 2.3× |
| IRWDIronwood Pharmaceuticals | 1.5× |
| ZVRAZevra Therapeutics | 4.4× |
| SPROSpero Therapeutics | 1.3× |
| COLLCollegium Pharmaceutical | 1.0× |
| ABUSArbutus Biopharma | 4.4× |
| Peer median | 1.4× |
Where Akebia Therapeutics ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Akebia Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.